Lasa Supergenerics Limited (NSE:LASA)
7.14
+0.01 (0.14%)
Jun 15, 2026, 3:29 PM IST
Lasa Supergenerics Revenue
In the fiscal year ending March 31, 2026, Lasa Supergenerics had annual revenue of 253.41M INR, down -82.82%. Lasa Supergenerics had revenue of -908.00K in the quarter ending March 31, 2026.
Revenue
253.41M
Revenue Growth
-82.82%
P/S Ratio
1.41
Revenue / Employee
3.84M
Employees
66
Market Cap
357.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 253.41M | -1.22B | -82.82% |
| Mar 31, 2025 | 1.47B | 430.26M | 41.20% |
| Mar 31, 2024 | 1.04B | -259.96M | -19.93% |
| Mar 31, 2023 | 1.30B | -66.97M | -4.88% |
| Mar 31, 2022 | 1.37B | -652.53M | -32.24% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ind-Swift Laboratories | 6.88B |
| Sigachi Industries | 4.86B |
| Balaxi Pharmaceuticals | 2.70B |
| Valiant Laboratories | 2.37B |
| Bafna Pharmaceuticals | 1.51B |
| Vaishali Pharma | 1.13B |
| Par Drugs and Chemicals | 1.08B |
| Alpa Laboratories | 1.06B |